Drug intelligence / Profile preview

CB501

Development stage: Preclinical
Lead developer: CentricsBio

Overview

CB501 is a preclinical-stage drug candidate being developed by CentricsBio for the treatment of autoimmune diseases. It is designed as a novel immunotherapeutic agent that aims to correct the immune system and address the underlying causes of autoimmune conditions while minimizing the systemic side effects associated with conventional immunosuppressive therapies, such as high-dose steroids or broad immunosuppressants. Detailed information regarding its specific molecular target and modality has not been publicly disclosed.

Beyond the preview

Go deeper on CB501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB501.

Explore the full profile